文献速递淋巴瘤

儿童与青少年肝脾T细胞淋巴瘤

Hepatosplenic T-cell lymphoma in children and adolescents.
PubMed 文献 · Blood Adv · 2025-01-01

本文综述儿童与青少年肝脾T细胞淋巴瘤(HSTCL)的临床与组织病理学特征及结局。该病在该年龄段极罕见,诊断依赖骨髓、脾或肝活检,常采用成人强化化疗方案后续异基因造血干细胞移植,但预后仍差,估计5年总生存率<15%。

要点

  • HSTCL在儿童与青少年中极罕见,诊断与治疗对病理学家和儿科肿瘤学家具有挑战性。
  • 诊断通常依赖骨髓、脾或肝活检,免疫表型常为CD2/3/7阳性、CD4/8阴性,多数有γδ T细胞受体重排。
  • 儿童与青少年患者常采用成人方案如强化细胞毒性化疗后行异基因造血干细胞移植,但估计5年总生存率<15%。

核心结论

  • 儿童与青少年HSTCL虽采用高度强化治疗,预后仍差,估计5年总生存率<15%。
  • HSTCL在儿童与青少年中的罕见性限制了准确的流行病学估计、临床经验、数据收集、治疗进展和监测建议。

研究设计与样本

  • 本文为综述,总结儿童与青少年HSTCL已知的临床与组织病理学特征及结局,并强调与成人的潜在区别。

主要发现

  • HSTCL以显著肝脾肿大、骨髓受累和轻微或无淋巴结肿大为特征。
  • 组织病理学特征包括小/中等大小淋巴细胞伴不规则核轮廓,阻塞脾或肝的血窦或肝窦。
  • 免疫表型通常显示CD2/3/7阳性、CD4/8阴性,多数病例有γδ T细胞受体重排。
  • 儿童与青少年患者中描述的一些遗传学区别包括7号和8号染色体异常以及涉及SETD2和STAT5B的突变。
  • 儿童与青少年HSTCL估计5年总生存率<15%。

关键数值与推荐

  • 诊断通常依赖骨髓、脾或肝活检。
  • 儿童与青少年患者常采用成人方案,如强化细胞毒性化疗方案后行异基因造血干细胞移植。
  • 复发/难治性疾病的数据更为有限。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • HSTCL在儿童与青少年中的罕见性限制了准确的流行病学估计、临床经验、数据收集、治疗进展和监测建议。
  • 复发/难治性疾病的数据更为有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatosplenic T-cell lymphoma (HSTCL) is an aggressive mature T-cell lymphoma characterized by significant hepatosplenomegaly, bone marrow involvement, and minimal or no lymphadenopathy. Primarily affecting young adults, it is exceptionally rare in children and adolescents. This makes diagnosis and treatment particularly challenging for pathologists and pediatric oncologists. Diagnosis typically relies on bone marrow, spleen, or liver biopsy, with histopathologic features including small/medium lymphoid cells with irregular nuclear contours that obstruct the sinuses or sinusoids of the spleen or liver. Immunophenotyping usually reveals CD2/3/7 positivity and CD4/8 negativity, with γδ T-cell receptor rearrangements in most cases. Some genetic distinctions described in pediatric and adolescent patients include chromosome 7 and 8 abnormalities and mutations involving SETD2 and STAT5B. Given the lack of standardized approaches, childhood and adolescent patients with HSTCL are often treated with adult protocols, such as intensive cytotoxic chemotherapy regimens followed by allogeneic hematopoietic stem cell transplantation. Despite these highly intensive treatments, the prognosis for HSTCL remains poor in children and adolescents, with an estimated 5-year overall survival of <15%. HSTCL's rarity in children and adolescents limits accurate epidemiological estimates, clinical experience, data collection, treatment advances, and surveillance recommendations. Data on relapsed/refractory disease are even more limited. This review summarizes known clinical and histopathologic features as well as outcomes specific to children and adolescents with HSTCL, highlighting potential distinctions from adults. We will also discuss future strategies to acquire additional biologic and molecular data, streamline diagnosis, and advance treatment approaches to ultimately improve outcomes for young patients with this deadly disease.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Schwartz LF, Devine KJ, Xavier AC, et al. Hepatosplenic T-cell lymphoma in children and adolescents. Blood Adv. 2025. PMID: 39874497. doi:10.1182/bloodadvances.2025015857

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。